Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease.

Aim: To compare the efficacy and safety of omeprazole-domperidone combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

Methods: In a comparative, randomized controlled, phase 4 study, outpatients with GERD were randomly allocated to either group 1 (omeprazole 20 mg + domperidone 30 mg) or group 2 (omeprazole 20 mg) in an equal ratio; 2 capsules daily in the morning were administered for 8 weeks.

Results: Sixty patients were enrolled.

[The micro-ecology of burn hospitals.].

The article analyzes agents of wound burn infection on departments of the Privolzhskii` Federal medical research center during last 2.5 years. The leading role in infection etiology in the burnt ones belongs to staphylococci.

[Treatment of chronic rhinitis in children].

This paper discusses involvement of intestinal dysbacteriosis in nasal inflammation. Altogether 42 children of preschool age with chronic rhinitis were examined. It was found that microbial changes in the nasal cavity were related to the degree of intestinal dysbacteriosis, which was detected in most patients.

[The choice of suture material in forming bile-diverting anastomoses].

In the experiment, it was established that the use of a synthetic thread of the noncapillary type with a small diameter, when microsurgical technique was employed, provided minimal damage, full-value adaptation of the membranes of the organs sutured, thus facilitating primary healing of anastomosis.

[Immediate results of parlodel treatment of patients with diffuse toxic goiter complicated by endocrine ophthalmopathy].

The authors reported the results of parlodel therapy of 18 patients with diffuse toxic goiter complicated by endocrine ophthalmopathy. The patients ranged in age from 24 to 59 with a period of disease from 3 months to 10 years and more. The drug was given for 6 weeks at a dose of 2.